295 MADISON AVENUE, NEW YORK, NY
Announces First Quarter 2026 Results
Portfolio Company to Pay Cash Dividend
Transdermal GFR Monitor and Reusable Sensor Receive CE Mark Under European Medical Device Regulation
Investor Presentation
Transdermal GFR Article Recognized as One of Five 2025 Editors’ Choice Articles
Next Generation TGFR TM System Receives FDA Approval
Announces Third Quarter 2025 Results
Q1
Q3
Q2
FY 2024
Notice of Exempt Offering of Securities
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Definitive Information Statement
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Amended Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload